Identifying Active Disease via Epigenetic Gene Signatures in Osteosarcoma Patients

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Npj Precision Oncology  https://doi.org/10.1038/s41698-026-01326-z
Dr. Evan W. Neczypor et al.

Points

Researchers identified specific 5-hydroxymethylcytosine epigenetic signals in the blood that correlate with active disease status in pediatric patients suffering from the rare and aggressive bone cancer known as osteosarcoma.
The study utilized the innovative nano-hmC-seal technique to map gene activity patterns from circulating cell-free DNA fragments which revealed a distinctive signature consisting of two hundred sixty-two osteosarcoma-related genes.
Validation results showed the test could successfully identify ten out of twelve patients with primary bone tumors while achieving an overall sensitivity of sixty-five percent for detecting active disease.
The signature was particularly strong in patients with primary tumors or bone metastases but was less detectable in those whose cancer had only spread to the lungs or lymph nodes.
This feasibility study suggests that epigenetic liquid biopsies could eventually complement radiation-heavy imaging scans to help doctors monitor treatment responses and identify early signs of cancer relapse more safely.

Summary

This study evaluated the feasibility of utilizing 5-hydroxymethylcytosine (5-hmC) profiles in plasma-derived cell-free DNA (cfDNA) as a biomarker for disease status in osteosarcoma patients. Given that osteosarcoma typically sheds low levels of circulating tumor DNA (ctDNA), making traditional liquid biopsies challenging, the research sought to determine if epigenetic modifications reflecting active gene expression could reliably distinguish between active disease and remission. Using the nano-hmC-seal technique, the team mapped patterns of open chromatin to identify a specific osteosarcoma gene signature in the bloodstream.

The investigation identified a signature of 262 genes in a Discovery cohort that differentiated osteosarcoma patients from healthy controls. In an independent Validation cohort, hierarchical clustering based on these signature genes successfully grouped 10 out of 12 samples from patients with primary disease or osseous metastases into a high-signal cluster. Conversely, 26 out of 33 samples from patients without active disease were correctly categorized into a low-signal cluster. Using a semi-quantitative scoring system, the assay demonstrated a sensitivity of 65% and a specificity of 64% for classifying active disease states.

The findings suggest that cfDNA 5-hmC profiling is a promising, minimally invasive tool for monitoring osteosarcoma, particularly for primary bone tumors and osseous spread. While the signature was less detectable in isolated pulmonary or lymph node metastases, the epigenetic patterns provided a distinctive recognizable pattern of bone biology and turnover. These results establish the technical feasibility of epigenetic liquid biopsies in rare pediatric cancers. Larger prospective trials are warranted to refine the gene signature and determine if this method can improve early relapse detection and guide clinical decision-making.

Link to the article: https://www.nature.com/articles/s41698-026-01326-z

References

Neczypor, E. W., Reisert, H., Moore, K., Zeldin, E., Dubin, R. A., Battle, L., He, C., Hayashi, M., Weiser, D. A., & Applebaum, M. A. (2026). 5-hydroxymethylcytosine profiles in circulating cell-free DNA associate with disease status in patients with osteosarcoma. Npj Precision Oncology, 10(1), 125. https://doi.org/10.1038/s41698-026-01326-z